ertiprotafib has been researched along with Disease Models, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattarai, BR; Chang, KJ; Cho, H; Lee, KH; Shrestha, S | 1 |
| Bhattarai, BR; Cho, H; Choi, JK; Shrestha, S | 1 |
1 trial(s) available for ertiprotafib and Disease Models, Animal
| Article | Year |
|---|---|
PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta).
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; I-kappa B Kinase; Phenylpropionates; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Thiophenes | 2007 |
1 other study(ies) available for ertiprotafib and Disease Models, Animal
| Article | Year |
|---|---|
Methylenedisalicylic acid derivatives: new PTP1B inhibitors that confer resistance to diet-induced obesity.
Topics: Adipocytes; Animals; Anti-Obesity Agents; Diet; Disease Models, Animal; Mice; Mice, Inbred C57BL; Obesity; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Salicylates; Weight Gain | 2007 |